Literature DB >> 8531139

5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation.

B L Roth1, E P Palvimaki, S Berry, N Khan, N Sachs, A Uluer, M S Choudhary.   

Abstract

The connection between agonist-induced desensitization and down-regulation of 5-hydroxytryptamine2A (5-HT2A) receptors was examined in a clonal cell line that stably expresses the 5-HT2A receptor. Brief (2-hr) and prolonged (24-hr) exposure to the agonist quipazine or the agonist 4-iodo-(2,5-dimethoxy)- phenylisopropylamine (DOI) diminished 5-HT2A receptor-mediated phosphoinositide hydrolysis; no change in 5-HT2A receptor number or affinity was measured after 24 hr of exposure to DOI or quipazine. Immunohistochemical studies demonstrated that a 24-hr exposure to DOI did not alter surface 5-HT2A receptor immunoreactivity. Western blot analysis with G alpha q- and G alpha 11-selective antibodies indicate that a 24-hr agonist exposure did not alter the levels of phospholipase C-dependent G proteins. These results suggest that desensitization after prolonged DOI exposure can occur via a process independent of the levels of phospholipase C-coupled G proteins. Studies with a mutant 5-HT2A receptor (F340L) indicated that binding per se is not sufficient for desensitization. Down-regulation of the protein kinase C isozymes alpha and epsilon by overnight exposure to phorbol-12,13-dibutyrate attenuated the intermediate phase (i.e., after 2-6 hr of agonist exposure) of DOI- and quipazine-induced desensitization. These results indicate that the intermediate phase of DOI-induced desensitization is mediated by the alpha- and/or epsilon-protein kinase C isozymes but that neither is involved in the later phase (i.e., after 24 hr of agonist exposure) of desensitization.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8531139

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

Review 1.  Serotonin receptor signaling and regulation via β-arrestins.

Authors:  Laura M Bohn; Cullen L Schmid
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-10-07       Impact factor: 8.250

2.  Neuronal localization of 5-HT type 2A receptor immunoreactivity in the rat basolateral amygdala.

Authors:  A J McDonald; F Mascagni
Journal:  Neuroscience       Date:  2007-02-28       Impact factor: 3.590

3.  Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation.

Authors:  Bryan L Roth
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

4.  Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling.

Authors:  Kelly A Jones; Deepak P Srivastava; John A Allen; Ryan T Strachan; Bryan L Roth; Peter Penzes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-04       Impact factor: 11.205

Review 5.  Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders.

Authors:  Marc Fakhoury
Journal:  Mol Neurobiol       Date:  2015-04-01       Impact factor: 5.590

6.  Inverse agonist abolishes desensitization of a constitutively active mutant of thyrotropin-releasing hormone receptor: role of cellular calcium and protein kinase C.

Authors:  H Grimberg; I Zaltsman; M Lupu-Meiri; M C Gershengorn; Y Oron
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

7.  Sustained treatment with a 5-HT(2A) receptor agonist causes functional desensitization and reductions in agonist-labeled 5-HT(2A) receptors despite increases in receptor protein levels in rats.

Authors:  Ju Shi; Michelle Landry; Gonzalo A Carrasco; George Battaglia; Nancy A Muma
Journal:  Neuropharmacology       Date:  2008-06-07       Impact factor: 5.250

Review 8.  Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.

Authors:  David Baumeister; Georgina Barnes; Giovanni Giaroli; Derek Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2014-08

Review 9.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

Review 10.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.